Windtree Therapeutics Inc. (WINT) Soars 14.63% on Nasdaq Compliance

On March 26, 2025, Windtree Therapeutics Inc. (WINT) shares rose 14.63% in pre-market trading, reflecting a significant turnaround in the company's stock performance.

Windtree Therapeutics has successfully regained compliance with Nasdaq's minimum bid price requirement, ensuring its continued listing on the exchange. The company's stock price has maintained above $1.00 for ten consecutive trading days, meeting the necessary criteria set by Nasdaq. This compliance was achieved through a 1-for-50 reverse stock split, effective February 20, 2025, which helped the company meet the minimum bid price requirement.

Windtree Therapeutics initially fell out of compliance on December 4, 2024, when its stock traded below the required $1.00 minimum closing bid price for 30 consecutive days. The company's efforts to restore compliance involved maintaining a minimum bid price of $1.00 for at least 10 consecutive trading days, which it successfully achieved as of February 21. Nasdaq will continue to monitor Windtree Therapeutics until March 20, 2026, to ensure sustained compliance.